Binary rhBMP-2 Composition for Bone and Vascular Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions using recombinant human bone morphogenetic protein-2 (rhBMP-2) face challenges in achieving both osteoinduction and angiogenesis due to high therapeutic doses required and the need for precise timing of factor administration, limiting their clinical applications.
Innovation Solution
A pharmaceutical composition combining glycosylated and non-glycosylated forms of rhBMP-2, where the glycosylation state affects biological activity, allowing non-glycosylated rhBMP-2 to induce angiogenesis at low concentrations and glycosylated rhBMP-2 to induce bone growth, with a binary growth factor composition optimizing their respective concentrations for synergistic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high doses of rhBMP-2 are used to achieve osteoinduction, then bone growth is promoted, but the therapeutic dose must be 100-1000-fold higher than in animals, limiting clinical applications
Solution Approach 1:
The invention segments the single rhBMP-2 molecule into two distinct forms: glycosylated rhBMP-2 (for osteoinduction) and non-glycosylated rhBMP-2 (for angiogenesis). This segmentation allows each form to perform its specialized function at physiologically relevant concentrations, eliminating the need for supraphysiological dosing required when using单一 rhBMP-2 for both functions simultaneously.
Solution Approach 2:
The invention applies local quality by赋予 different functional properties to different molecular forms of rhBMP-2. The glycosylated form specifically targets osteoblast differentiation, while the non-glycosylated form specifically targets endothelial cell angiogenesis. This functional differentiation at the molecular level enables precise control over biological outcomes at physiological concentrations.
2Quantity of substance
If sequential application of multiple growth factors (rhVEGF followed by rhBMP-2) is used to reduce dose, then both angiogenesis and osteoinduction are achieved, but precise timing of administration is required
Solution Approach 1:
The invention merges the previously separate sequential administration protocols into a single simultaneous application. By combining glycosylated rhBMP-2 and non-glycosylated rhBMP-2 in one composition, both angiogenesis and osteoinduction are achieved concurrently without requiring multiple separate administrations or precise timing coordination.
Solution Approach 2:
The invention creates a universal composition that performs multiple functions (angiogenesis and osteoinduction) simultaneously through a single application. The binary growth factor composition acts as a multi-functional system where both biological outcomes are achieved through one treatment event, eliminating the need for complex sequential protocols.
3Quantity of substance
If non-glycosylated rhBMP-2 is used for angiogenesis, then proangiogenic function is achieved at picomolar concentrations, but this function was previously attributed to combinations or contaminations with other proangiogenic factors
Solution Approach 1:
The invention extracts and isolates the genuine proangiogenic function from rhBMP-2 by using the non-glycosylated form produced in E. coli, which lacks contamination with other proangiogenic factors. This purification approach demonstrates that rhBMP-2 itself possesses intrinsic angiogenic activity at picomolar concentrations, independent of VEGF or other growth factor contaminants.
Data Source
AI summary
The present invention is directed to a pharmaceutical composition comprising glycosylated rhBMP-2 and non-glycosylated rhBMP-2 for promoting osteoinduction and angiogenesis, either in unary form for angiogenesis alone by non-glycosylated rhBMP-2 or in particular in a homologous binary growth factor composition for bone induction comprising glycosylated rhBMP-2 and non-glycosylated rhBMP-2.